Decoding mutational signatures in breast cancer: Insights from a multi-cohort study

被引：0
作者：
Betz, Margaux [1 ]
Witz, Andrea [1 ]
Dardare, Julie [2 ]
Michel, Cassandra [1 ]
Massard, Vincent [3 ]
Boidot, Romain [4 ]
Gilson, Pauline [1 ]
Merlin, Jean-Louis [1 ]
Harle, Alexandre [1 ]
机构：
[1] Univ Lorraine, Inst Cancerol Lorraine, Serv Biopathol, CNRS,UMR 7039,CRAN, F-54519 Vandoeuvre Les Nancy, France
[2] Inst Canc Lorraine, Serv Biopathol, F-54519 Vandoeuvre Les Nancy, France
[3] Inst Cancerol Lorraine, Dept Oncol Med, F-54519 Vandoeuvre Les Nancy, France
[4] Ctr GF Leclerc, Res Platform Biol Oncol, Dijon, France
来源：
TRANSLATIONAL ONCOLOGY | 2025年 / 53卷
关键词：
Mutational signature; Breast cancer; Next generation sequencing; Genomic database; IN-SITU HYBRIDIZATION; LANDSCAPE; DECALCIFICATION; EDTA;
D O I：
10.1016/j.tranon.2025.102315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: Diagnosis and treatment decisions of hormonal breast cancers (BC) are now guided by genomic mutations determination, combined into mutational signatures, and provide insight into the patients' genomic landscape. This work aims to compare genomic data and signatures extracted from tissue samples collected in the CICLADES study to existing cohorts. Ultimately, the goal is to prove the accuracy of smaller cohorts and provide new relevant data. Materials and methods: DNA from patients of the CICLADES cohort was extracted, sequenced, and custom filtering was applied to the resulting files. Genomic data was pulled from 6 BC cohorts available on cBioPortal.com. In total, 2303 samples were analyzed. Mutational signatures were extracted and matched to known signatures of the Catalogue of Somatic Mutations in Cancer (COSMIC). Tumor Mutation Burden (TMB) and hypermutation were estimated and compared between samples. Results: PIK3CA and TP53 represented the two genes highly mutated across all cohorts. TMB was similar between the CICLADES and CBSM groups, however the MSKCC population showed a significantly higher TMB than both. Nine signatures were extracted, with recurring Single Base Substitutions (SBS) signatures like SBS1, SBS2 and SBS5. The presence of APOBEC-specific signatures was concordant with cohorts presenting APOBEC enrichment. The mean number of mutations was significantly higher in enriched samples for each analyzed cohort. Conclusion: The use of comprehensive genomic profiling provided accurate evaluation of the TMB and extraction of signatures consistent with published literature. The genomic analysis of the tissue samples of the CICLADES cohort brings new and relevant data, comparable to results found in bigger cohorts.
引用
收藏
页数：7
相关论文
共 27 条
  • [1] Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., (2024)
  • [2] Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Et al., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 3, pp. 209-249, (2021)
  • [3] Barzaman K., Karami J., Zarei Z., Hosseinzadeh A., Kazemi M.H., Moradi-Kalbolandi S., Et al., Breast cancer: biology, biomarkers, and treatments, Int. Immunopharmacol., 84, (2020)
  • [4] Tsang J.Y.S., Tse G.M., Molecular classification of breast cancer, Adv. Anat. Pathol., 27, 1, pp. 27-35, (2020)
  • [5] Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 4785, pp. 177-182, (1987)
  • [6] Rakha E.A., Pareja F.G., New advances in molecular breast cancer pathology, Semin. Cancer Biol., 72, pp. 102-113, (2021)
  • [7] Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., Et al., Signatures of mutational processes in human cancer, Nature, 500, 7463, pp. 415-421, (2013)
  • [8] Alexandrov L.B., Kim J., Haradhvala N.J., Huang M.N., Tian Ng A.W., Wu Y., Et al., The repertoire of mutational signatures in human cancer, Nature, 578, 7793, pp. 94-101, (2020)
  • [9] Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Et al., Standards and Guidelines for the interpretation of sequence Variants: a joint consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet. Med. Off. J. Am. Coll. Med. Genet., 17, 5, pp. 405-424, (2015)
  • [10] Krug K., Jaehnig E.J., Satpathy S., Blumenberg L., Karpova A., Anurag M., Et al., Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy, Cell, 183, 5, pp. 1436-1456, (2020)
123